---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-24-027393"
form_type: "8-K"
ticker: "AUTL"
cik: "0001730463"
company_name: "Autolus Therapeutics plc"
filed_at: "2024-02-08T23:59:59+00:00"
generated_at: "2026-06-06T05:44:04.694729+00:00"
event_type: "m_and_a"
sentiment: "positive"
materiality_score: 0.85
calibrated_materiality_score: 0.85
confidence: "high"
source: SEC EDGAR
---

# Autolus enters $200M equity deal and strategic CAR-T collaboration with BioNTech

## Summary
- BioNTech invests $200M in Autolus ADS at $6.00 per share, plus $50M upfront under license agreement.
- Autolus grants BioNTech exclusive license to certain binders; total potential milestones up to $582M.
- BioNTech gets rights to use Autolus' UK manufacturing capacity to accelerate BNT211 into pivotal trials.
- BioNTech receives up to mid-single-digit royalty on obe-cel net sales; Autolus retains full control of obe-cel.
- BioNTech gains option to co-commercialize AUTO1/22 and AUTO6NG and a board nomination right.

## SEC filing metadata
- accession: 0001193125-24-027393
- form_type: 8-K
- ticker: AUTL
- cik: 0001730463
- company_name: Autolus Therapeutics plc
- filed_at: 2024-02-08T23:59:59+00:00
- event_type: m_and_a
- sentiment: positive
- materiality_score: 0.85
- calibrated_materiality_score: 0.85
- confidence: high
- sec_items: 1.01, 3.02, 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/0001193125-24-027393-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/d782679d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-24-027393
- JSON: https://secwatch.observer/filing/0001193125-24-027393.json
- Plain text: https://secwatch.observer/filing/0001193125-24-027393.txt

## Key facts
- Material Agreements
  Autolus Therapeutics plc entered into License Agreement with BioNTech SE valued at up to $582 million (effective 2024-02-06).
  - Action: entry
  - Agreement: license
  - Counterparty: BioNTech SE
  - Value: up to $582 million
  - Effective: 2024-02-06
  source text: On February 6, 2024 (the “ Execution Date ”), Autolus Therapeutics plc (the “ registrant ”) and the registrant’s wholly owned subsidiaries, Autolus Limited and Autolus Holdings (UK) Limited (together, with the registrant, the “ Company ”) entered into a License and Option Agreement (the “ License Agreement ”) with BioNTech SE (“ BioNTech ”)
  evidence_url: https://www.sec.gov/Archives/edgar/data/1730463/000119312524027393/0001193125-24-027393-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.